TRC105 and clinical trials in mCRPC

TRC105 is a novel angiogenesis inhibitor being developed by TRACON Pharmaceuticals that is expected to have activity against a wide variety of solid cancers, including advanced forms of prostate cancer.

The drug is a monoclonal antibody that targets a specific cell membrane receptor called CD105 that is found in endothelial cells. The CD105 receptor is a key component in the formation of new blood vessels (angiogenesis). Because tumor growth and tumor metastasis are dependent on angiogenesis, and because CD105 is strongly expressed in the endothelial cells that make up the blood vessels of most solid cancers, it is hoped that TRC105 will be able to inhibit angiogenesis and attack the preformed blood vessels in established and in developing tumors.

TRC105 is currently in Phase I/II clinical trials for metastatic, castration-resistant prostate cancer (mCRPC), and TRACON is only a relatively small company, but according to a media release early this morning the company has been able to raise sufficient funding to support their current and proposed clinical trials program for development of this drug for potential treatment of mCRPC and other indications.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: